CeloNova BioSciences Introduces a New Class of Coronary Stent: The CATANIA(TM) Coronary Stent System with NanoThin Polyzene(R)-F

    ATLANTA, Jan. 20 /CNW/ -- CeloNova BioSciences, Inc. ("CeloNova"),
leading and accelerating healthcare solutions through the development of
innovative medical devices, today announced breakthrough results from the
ATLANTA study of the CATANIA(TM) Coronary Stent System with NanoThin
Polyzene(R)-F at the 20th Annual International Symposium on Endovascular
Therapy (ISET).
    (Photo:  http://www.newscom.com/cgi-bin/prnh/20080120/CLSU002 )
    Corrado Tamburino, MD, President of the Italian Society of Interventional
Cardiology, Chief of Interventional Cardiology at Ferrarotto Hospital and Full
Professor of Cardiology at the University of Catania is Principal Investigator
for the ATLANTA study. Dr. Tamburino noted, "I perform many angioplasties in
each single day, many, and I am totally impressed by the performance of this
stent in a very complex patient population. No thrombosis. Low binary
restenosis. No MIs. This may be an answer to the problems we are facing with
other stent systems."
    The CATANIA(TM) Stent System with NanoThin Polyzene(R)-F, dubbed "The
CAT" by cardiologists who have used the product, has completed CE Marking and
is available for sale anywhere the CE Mark is accepted.  Advantages include:

    -- Early and complete vessel healing, as early as 30 days.
    -- Patients can discontinue dual anti-platelet therapy after only one
    -- Protection from stent thrombosis
    -- The Polyzene(R)-F surface treatment is bacterial-resistant
    "The FDA has cautioned physicians about a small but significant increased
risk of stent thrombosis for patients with drug-eluting stents. Now, Britain's
National Institute for Health and Clinical Excellence is considering
restrictions on DES because they are not cost-effective for most patients and
because of uncertainties about safety.  Polyzene(R)-F seems to solicit a
positive biological response that treats the stent as accepted part of the
vessel. As a result, 'The CAT' patients have excellent outcomes and can be
free from the medical complications and financial burden associated with
indefinite anti-platelet therapy," stated Thomas A. Gordy, President and Chief
Executive Officer.
    About CeloNova BioSciences, Inc.
    Headquartered in Newnan, near Atlanta, Georgia, CeloNova BioSciences,
Inc., is a developer of novel medical devices that are then enhanced by one of
the Company's proprietary materials, Polyzene(R)-F. Polyzene(R)-F is highly
lubricious, anti-inflammatory, and bacterial-resistant making it an ideal
surface treatment for implanted medical devices. The Company's current
products include its Embozene(TM) Color-Advanced Microspheres and the
CATANIA(TM) Coronary Stent System with NanoThin Polyzene(R)-F. Other
innovative devices are currently in the company's developmental pipeline. For
more information, please visit www.celonova.com.

    Thomas A. Gordy
    President and Chief Executive Officer
    +1 770-502-0304

For further information:

For further information: Thomas A. Gordy, President and Chief Executive 
Officer, CeloNova BioSciences, Inc., +1-770-502-0304 Web Site:

Organization Profile


More on this organization

Custom Packages

Browse our custom packages or build your own to meet your unique communications needs.

Start today.

CNW Membership

Fill out a CNW membership form or contact us at 1 (877) 269-7890

Learn about CNW services

Request more information about CNW products and services or call us at 1 (877) 269-7890